CClinicalTrials.gg
Sign In
WithdrawnNCT02053961Updated Jan 25, 2018

Deep TMS of the Left Auditory Cortex Using the HMCIPCC Coil, in the Treatment of Patients With Tinnitus.

A Phase 2 interventional study of Deep Transcranial Magnetic Stimulation and Deep Transcranial Magnetic Stimulation in Tinnitus, sponsored by Brainsway. Withdrawn at 1 site in Israel. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-01-25.

Sponsored by Brainsway · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Study summary

The study is a double-blind study designed to evaluate the efficacy of deep transcranial magnetic stimulation (deep TMS) of the left auditory cortex using the HMCIPCC coil, in the treatment of patients with tinnitus

Read the detailed description

Stages of the study:

A. Patient recruitment stage: hearing tests battery including: otoscopy, tympanometry, pure-tone audiometry - 0 to 20 dB HL; 21 to 60 dB HL and more than 60 dB HL, tinnitus matching, TQ and VAS.

B. Patients will be assign to one of two study groups, Deep TMS over the left auditory cortex and Sham. .

C. TMS Acute treatment phase:

TMS treatment will be administer for two weeks: 5 days a week for half an hour. Before each TMS treatment session, patients will undergo training exercises designed to stimulate the neural network associated with attention processes Monitoring for evaluation of treatment efficacy and side effects will be perform on a daily basis. . The overall time of each session is estimate to be 1 hour.

D. TMS Maintenance phase:

Four additional TMS treatment sessions will be administered once weekly for another 4 weeks.

Long-term durability of treatment effect will be assessed up to 90 days after the last TMS session.

E. TMS treatment program:

  1. The subject will be required to use earplugs to minimize risk of hearing impairment.
  2. Motor threshold stimulation intensity will be determined prior to each TMS session. .
  3. Subjects will receive either active TMS or sham treatment, depending on the experimental group to which they were assign. During the first 2 weeks, five treatment sessions will be administer each week. During the following 4 weeks, one treatment will be administer weekly. Overall, each subject will receive 16 TMS session in 6 treatment weeks.

F. Safety:

Throughout the trial subjects will be constantly monitored by a physician. Any adverse effect or subjective discomfort experienced will be documented and addressed.

Magnetic stimulation treatment will be administered by an operator trained and certified by Brainsway.

Subjects who wish to withdraw from the study will be free to do so at any point.

Drugs belonging to benzodiazepine class will be permitted if necessary at daily doses up to the equivalent of 2 mg Lorazepam (Lorivan).

02

Conditions studied

  • Tinnitus

Browse trials for

03

In context

Tinnitus

412 studies on the registry are indexed under Tinnitus; 87 are open to participants now.

Browse Tinnitus studies →

Lead sponsor

Brainsway is the lead sponsor of 21 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Men and women aged 20-70.
  2. Self-report of tinnitus in one or both ears, persisting for over a year, with no other hearing impairment.
  3. Mild/moderate/severe tinnitus. Severity of tinnitus will be diagnosed using the TQ (Goebel \& Hiller) / the THI (Newman \& Jacobson).
  4. Unresponsive to standard tinnitus medication.
  5. Normal results on pure tone audiometry testing (threshold ≤ 25 dB hearing level in all frequencies from 250 to 8000 Hz).
  6. Normal middle ear status was demonstrated by tympanometry, stapedius reflex tests, and otoscopy.
  7. Normal results on neurological and physiological examinations.
  8. Gave their oral and written consent to participate in the trial.

Exclusion criteria

Exclusion Criteria:

  1. A DSM-IV Axis-I psychiatric disorder.

  2. Use of medication that may be a risk factor for seizures, such as:

    antipsychotic medication; high dosage of antidepressant medication; drugs belonging to benzodiazepine class will be permitted if necessary at daily doses up to the equivalent of 2 mg Lorazepam (Lorivan)' any other drug that is considered a risk factor for seizures by the Principal Investigator.

  3. History of intolerance to TMS.
  4. Diagnosis of a severe personality disorder according to the DSM-IV.
  5. Current suicidal ideation.
  6. Uncontrolled hypertension.
  7. History of epilepsy, seizure, or heat convulsion.
  8. History of epilepsy or seizure in first degree relatives.
  9. History of head injury or stroke.
  10. History of any metallic particles in the head (except dental fillings).
  11. History of surgery entailing metallic implants or known history of any metallic particles in the eye, implanted cardiac pacemakers, cochlear implants, use of neurostimulators, or any medical pumps.
  12. History of drug or alcohol abuse.
  13. Inability to communicate adequately with examiner.
  14. Participation in another clinical study, either concurrent with this trial or in the 3 months preceding it.
  15. Inability to sign a consent form.
  16. Pregnancy or inadequate birth control.
  17. Severe hearing impairment.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    1Hz dTMS Real

    This group will receive dTMS real treatment of 1Hz

    Device: Deep Transcranial Magnetic Stimulation

  • Sham comparator
    1HZ dTMS SHAM

    This group will receive 1HZ dTMS SHAM treatment

    Device: Deep Transcranial Magnetic Stimulation

Interventions

  • DeviceDeep Transcranial Magnetic Stimulation

    1Hz dTMS real treatment

  • DeviceDeep Transcranial Magnetic Stimulation

    1Hz dTMS SHAM treatment

06

What researchers measure

Primary outcomes

  1. TQ - Tinnitus questionnaire

    Time frame: 90 days after the last treatment session

Secondary outcomes

  1. VAS (100 - worst possible tinnitus related discomfort; 0 - wellness)

    Time frame: baseline, week 1: day 1-5, and week 2: day 1-5

07

Study locations

1 site
  • Wolfson Hospital
    Holon, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02053961
Lead sponsor
Brainsway
Responsible party
Sponsor
First posted
Feb 4, 2014
Start date
Jan 2014 (estimated)
Primary completion
Jan 2016 (estimated)
Completion
Jan 2016 (estimated)
Last update
Jan 25, 2018

Study contacts

Yair Lampel, Prof.
principal investigator · Neurology Department, Wolfson Hospital, Israel

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Tinnitus→

Other studies from this sponsor

Brainsway

Start the discussion